Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jacques Letreut
Observed names:
J. LeTreut,
J. Letreut,
Letreut, Jacques
Institution:
Hôpital Européen
Observed institutions:
Assistance Publique Hôpitaux de Marseille,
Assistance Publique – Hôpitaux de Paris,
Centre Hospitalier Intercommunal Aix-Pertuis,
Hôpital Européen,
Centre Hospitalier Universitaire de Caen Normandie,
Centre Hospitalier Universitaire de Limoges
show all 6
OpenAlex ID:
A5011586516
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
2020
·
Nathalie Baize
, Isabelle Monnet
, et al.
·
The Lancet Oncology
·
204
PDF
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics
2018
·
Léonie Ferrer
, Matteo Giaj Levra
, et al.
·
Journal of Thoracic Oncology
·
176
PDF
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies
2014
·
T. Moran
, J. Wei
, et al.
·
Annals of Oncology
·
35
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
2020
·
Dominique Arpin
, Marie-Christine Charpentier
, et al.
·
Therapeutic Advances in Medical Oncology
·
31
PDF
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01
2015
·
Pierre Fournel
, Alain Vergnenégre
, et al.
·
European Journal of Cancer
·
28
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
2015
·
C. Raynaud
, L. Greillier
, et al.
·
BMC Cancer
·
24
PDF
An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study
2007
·
H. LeCaer
, P. Fournel
, et al.
·
Critical Reviews in Oncology/Hematology
·
23
Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
2019
·
Jean-Bernard Auliac
, Pascal Dô
, et al.
·
Advances in Therapy
·
20
PDF
Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer
2004
·
A. Vergnenègre
, C. Daniel
, et al.
·
Lung Cancer
·
14
Évaluation multicentrique et randomisée de l’impact des conseillers en environnement intérieur sur le contrôle de l’asthme : l’étude ECENVIR
2022
·
J.P. Gangneux
, H. Morel
, et al.
·
Revue française d'allergologie
·
7
O-091 A randomized phase II trial of docetaxel alone and in combinationwith gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer
2005
·
G. Robinet
, L. Falchero
, et al.
·
Lung Cancer
·
3
Proportion of lung cancer patients eligible for screening in France: Data from the KBP-2020-CPHG study
2026
·
Sebastien Couraud
, Emmanuel Grolleau
, et al.
·
Lung Cancer
·
1
1864P Study on the real-life use of G-CSF in patients with lung cancer: Secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG
2024
·
D. Debieuvre
, L. Falchero
, et al.
·
Annals of Oncology
·
1
PDF
Randomized trial of adjuvant chemotherapy (Cx) with cisplatin plus gemcitabine (CG) versus cisplatin plus docetaxel (CD) in patients (pts) with completely resected non-small cell lung cancer (NSCLC) with quality of life (QoL) as the primary objective
2009
·
F. Barlesi
, C. Chouaid
, et al.
·
Journal of Clinical Oncology
·
1
Explore-ALK (GFPC 03-2019) : une étude prospective, multicentrique de patients porteurs d’un CBNPC ALK réarrangé
2025
·
C. Decroisette
, R. Descourt
, et al.
·
Revue des Maladies Respiratoires Actualités
Qualité de vie (QdV) au diagnostic pour les patients porteurs d’un CBNPC de stade III non résécable : résultats de l’étude prospective nationale française OBSTINATE (GFPC 06-2019)
2025
·
C. Ricordel
, C. Christos
, et al.
·
Revue des Maladies Respiratoires Actualités
Incidence et suivi de cancer bronchopulmonaire non à petites cellules mutées EGFR traité par chirurgie : étude EXERPOS GFPC
2023
·
J.B. Auliac
, Y. Simoneau
, et al.
·
Revue des Maladies Respiratoires Actualités
P3.02b-127 NSCLC Patients Harboring HER2 Mutation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14
2017
·
Jean Bernard Auliac
, Pascal Do
, et al.
·
Journal of Thoracic Oncology
PDF
42 Essai de phase II de l’association cisplatine-témozolomide dans les métastases cérébrales des cancers bronchiques non à petites cellules (CNPC). Etude glot-GFPC
2004
·
G. Robinet
, J.L. Breton
, et al.
·
Revue des Maladies Respiratoires
P-222 Phase II study of temozolomide and cisplatin in non small cell lung cancer patients with brain metastasis (GLOT-GFPC 01/01)
2003
·
Pierre-Jean Souquet
, Herve Lena
, et al.
·
Lung Cancer
Show more works
View as search
Works count:
21
Citation count:
568
H-index:
9
I10-index:
9
Year
Topic
Type